Workflow
四环生物(000518) - 2014 Q3 - 季度财报
JSSHJSSH(SZ:000518)2014-10-30 16:00

Financial Performance - Net profit attributable to shareholders increased by 84.00% to CNY 5,818,533.48 for the current period[7] - The company reported a significant increase in net profit year-to-date, up 1,348.14% to CNY 28,685,024.23[7] - Basic earnings per share rose by 83.87% to CNY 0.0057 for the current period[7] - Operating revenue decreased by 1.58% to CNY 52,982,712.79 compared to the same period last year[7] - The weighted average return on equity increased to 0.86%, up from 0.44%[7] Cash Flow and Assets - Net cash flow from operating activities showed a decline of 134.86% to CNY -7,840,172.57 year-to-date[7] - Cash and cash equivalents decreased by 86.50% from CNY 139,763,039.84 to CNY 18,863,896.28 due to investments in GMP transformation and equipment purchases[15] - Net cash flow from operating activities decreased by 134.86% from CNY 22,488,344.21 to CNY -7,840,172.57, driven by lower cash receipts from sales[15] - The company reported a significant decrease in net cash flow from financing activities, dropping by 143.78% from CNY 13,498,754.70 to CNY -5,909,410.69, as it repaid short-term loans[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 160,492[11] - The largest shareholder, Guangzhou Shengjing Investment Co., Ltd., holds 3.89% of the shares, totaling 40,000,000 shares[11] Asset Management - Accounts receivable increased by 33.15% from CNY 72,718,442.30 to CNY 96,823,330.26, attributed to new receivables from Beijing Sihuan[15] - Prepaid expenses surged by 103.91% from CNY 82,742,771.49 to CNY 168,720,400.18, mainly for GMP transformation and equipment prepayments[15] - Long-term deferred expenses decreased by 56.25% from CNY 128,000.00 to CNY 56,000.00, reflecting monthly amortization of renovation costs[15] - Financial expenses dropped significantly by 102.50% from CNY -2,675,042.03 to CNY 66,927.80 due to reduced borrowing[15] - Asset impairment losses increased by 110.58% from CNY 1,539,517.57 to CNY 3,241,945.67, as additional bad debt provisions were made compared to the previous year[15] - Cash paid for fixed assets and other long-term assets rose by 680.89% from CNY 11,843,444.07 to CNY 92,484,521.44, primarily for GMP transformation and equipment prepayments[15] Project Development - The company is facing uncertainty regarding the production start date of the 200,000-ton coal tar hydrogenation project due to a lack of construction funds[17]